Epizyme Company Profile (NASDAQ:EPZM)

About Epizyme (NASDAQ:EPZM)

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EPZM
  • CUSIP: N/A
  • Web: www.epizyme.com
  • Market Cap: $894.53 million
  • Outstanding Shares: 58,466,000
Average Prices:
  • 50 Day Moving Avg: $13.62
  • 200 Day Moving Avg: $14.60
  • 52 Week Range: $7.02 - $18.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.12
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $17.06 million
  • Price / Sales: 52.43
  • Book Value: $2.57 per share
  • Price / Book: 5.95
  • EBIDTA: ($120,120,000.00)
  • Net Margins: -1,376.33%
  • Return on Equity: -63.10%
  • Return on Assets: -49.92%
  • Current Ratio: 7.71%
  • Quick Ratio: 7.71%
  • Average Volume: 777,811 shs.
  • Beta: 2.3
  • Short Ratio: 16.38

Frequently Asked Questions for Epizyme (NASDAQ:EPZM)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) issued its earnings results on Friday, August, 4th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.08. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The firm's revenue for the quarter was up 2027.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS. View Epizyme's Earnings History.

Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?

10 brokerages have issued 12 month price targets for Epizyme's shares. Their forecasts range from $20.00 to $28.00. On average, they expect Epizyme's stock price to reach $24.43 in the next year. View Analyst Ratings for Epizyme.

What are analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:

  • 1. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the  company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth. Loss estimates have narrowed mostly stable lately ahead of the Q2 results. Epizyme has a positive record of earnings surprises in the recent quarters." (7/18/2017)
  • 2. Cann analysts commented, "Epizyme, Inc. announced today that the US Food and Drug Administration has granted Orphan Drug designation to Tazemetostat, for the treatment of patients with soft tissue sarcoma (STS). Management reported they are looking forward to continued engagement with FDA on Tazemetostat for rapid development in both solid tumors and hematological malignancies. Orphan Drug status for Tazemetostat supports our expectation that Epizyme could launch it in 2018. While the company has only guided to a goal of filing Tazemetostat with FDA by early 2018, we anticipate the drug could be approved and launched in the same year, due to the high unmet need in the settings where it is being developed: rare hematologic and solid tumor cancers." (6/21/2017)
  • 3. Cowen and Company analysts commented, "Abstracts from ICML further support BGB-3111’s efficacy profile as being superior." (6/7/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board
  • Robert B. Bazemore Jr., President, Chief Executive Officer, Director
  • Andrew E. Singer, Executive Vice President - Finance and Administration, Chief Financial Officer, and Treasurer
  • Matthew Ros, Chief Operating Officer
  • Peter T.C. Ho M.D., Ph.D., Executive Vice President, Chief Medical Officer
  • Susan E. Graf, Chief Business Officer
  • Kevin T. Conroy, Director
  • Andrew R. Allen M.D. Ph.D., Independent Director
  • Kenneth M. Bate, Independent Director
  • Carl S. Goldfischer M.D., Independent Director

Who owns Epizyme stock?

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (10.73%), Palo Alto Investors LLC (9.75%), FMR LLC (9.72%), Vanguard Group Inc. (5.86%), Jennison Associates LLC (3.22%) and State Street Corp (3.02%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould. View Institutional Ownership Trends for Epizyme.

Who sold Epizyme stock? Who is selling Epizyme stock?

Epizyme's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Tekla Capital Management LLC, Jennison Associates LLC, JPMorgan Chase & Co., Schwab Charles Investment Management Inc., California State Teachers Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.

Who bought Epizyme stock? Who is buying Epizyme stock?

Epizyme's stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, State Street Corp, Bain Capital Public Equity Management LLC, Vanguard Group Inc., OxFORD Asset Management LLP, Federated Investors Inc. PA, Voya Investment Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.

How do I buy Epizyme stock?

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of Epizyme stock can currently be purchased for approximately $15.30.

MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.43 (59.66% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Leerink SwannReiterated RatingOutperform$31.00 -> $28.00MediumView Rating Details
8/7/2017HC WainwrightReiterated RatingBuyMediumView Rating Details
8/5/2017Royal Bank Of CanadaSet Price TargetBuy$20.00HighView Rating Details
6/21/2017CannReiterated RatingBuy$26.00MediumView Rating Details
6/16/2017Citigroup Inc.Boost Price TargetBuy$20.00 -> $22.00LowView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$26.00HighView Rating Details
6/7/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/18/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> OutperformLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
(Data available from 8/23/2015 forward)


Earnings History for Epizyme (NASDAQ:EPZM)
Earnings by Quarter for Epizyme (NASDAQ:EPZM)
Earnings History by Quarter for Epizyme (NASDAQ EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2017Q2 2017($0.56)($0.48)$3.95 million$10.00 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.63)($0.56)$0.49 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.65)($0.60)$0.61 million$0.48 millionViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$0.57 million$6.58 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)$0.61 million$0.47 millionViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)$0.58 million$0.47 millionViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)$0.66 million$0.56 millionViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$8.75 million$0.36 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.23 million$0.74 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$6.48 million$0.91 millionViewN/AView Earnings Details
3/12/2015Q414($0.54)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.54)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.46)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.48)($0.22)$7.67 million$13.39 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Epizyme (NASDAQ:EPZM)
2017 EPS Consensus Estimate: ($2.60)
2018 EPS Consensus Estimate: ($2.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.65)($0.63)($0.64)
Q2 20174($0.68)($0.41)($0.60)
Q3 20174($0.74)($0.59)($0.67)
Q4 20174($0.84)($0.55)($0.70)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.54)($0.54)($0.54)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)


Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Epizyme (NASDAQ:EPZM)
Insider Ownership Percentage: 25.20%
Institutional Ownership Percentage: 81.24%
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Peter Tai-Ching HoInsiderSell15,000$13.44$201,600.00View SEC Filing  
6/30/2017Andrew E SingerCFOSell3,024$15.50$46,872.00View SEC Filing  
6/26/2017Peter Tai-Ching HoInsiderSell15,000$14.87$223,050.00View SEC Filing  
6/6/2017Robert A CopelandInsiderSell2,500$13.45$33,625.00View SEC Filing  
5/25/2017Peter Tai-Ching HoInsiderSell15,000$16.11$241,650.00View SEC Filing  
5/2/2017Robert A CopelandInsiderSell5,000$17.44$87,200.00View SEC Filing  
4/4/2017Robert A CopelandInsiderSell5,000$16.36$81,800.00View SEC Filing  
3/31/2017Andrew E SingerCFOSell2,013$17.09$34,402.17View SEC Filing  
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.52View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.39View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.20View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Epizyme (NASDAQ:EPZM)
Latest Headlines for Epizyme (NASDAQ:EPZM)
americanbankingnews.com logoEpizyme, Inc. (EPZM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 23 at 5:06 AM
globenewswire.com logoEpizyme Announces Leadership Transition for Finance Organization - GlobeNewswire (press release)
globenewswire.com - August 16 at 5:09 AM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - August 16 at 12:22 AM
americanbankingnews.com logoLeerink Swann Reiterates Outperform Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - August 9 at 10:58 PM
nasdaq.com logoEpizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2 - Nasdaq
www.nasdaq.com - August 8 at 6:02 AM
finance.yahoo.com logoEpizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : August 7, 2017
finance.yahoo.com - August 7 at 6:36 PM
americanbankingnews.com logoRoyal Bank Of Canada Analysts Give Epizyme Inc (EPZM) a $20.00 Price Target
www.americanbankingnews.com - August 6 at 1:20 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - August 5 at 2:56 PM
finance.yahoo.com logoEdited Transcript of EPZM earnings conference call or presentation 4-Aug-17 12:00pm GMT
finance.yahoo.com - August 5 at 4:42 AM
globenewswire.com logoEpizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress - GlobeNewswire (press release)
globenewswire.com - August 4 at 11:39 PM
finance.yahoo.com logoInvestor Network: Epizyme, Inc. to Host Earnings Call
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme (EPZM) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoBiotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring
finance.yahoo.com - August 4 at 6:35 PM
finance.yahoo.com logoEpizyme reports 2Q loss
finance.yahoo.com - August 4 at 6:35 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - August 4 at 5:02 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Scheduled to Post Quarterly Earnings on Friday
www.americanbankingnews.com - August 3 at 8:08 PM
finance.yahoo.com logoFeatured Company News - US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
finance.yahoo.com - August 3 at 3:50 PM
globenewswire.com logoUS Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 5:00 AM
nasdaq.com logoWhat to Expect from Epizyme (EPZM) This Earnings Season? - Nasdaq
www.nasdaq.com - August 2 at 5:00 AM
finance.yahoo.com logoUS Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
finance.yahoo.com - August 1 at 6:59 PM
globenewswire.com logoEpizyme Announces Date of Second Quarter Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - July 31 at 6:06 PM
finance.yahoo.com logoEpizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 31 at 6:06 PM
americanbankingnews.com logo$3.70 Million in Sales Expected for Epizyme, Inc. (NASDAQ:EPZM) This Quarter
www.americanbankingnews.com - July 30 at 7:22 AM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 5:58 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 29 at 7:45 AM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - July 28 at 6:29 PM
americanbankingnews.com logoPeter Tai-Ching Ho Sells 15,000 Shares of Epizyme, Inc. (EPZM) Stock
www.americanbankingnews.com - July 26 at 8:23 PM
streetinsider.com logoEpizyme (EPZM) Reports Tazemetostat to be Evaluated in NCI's Recently Initiated NCI-COG Pediatric MATCH Trial - StreetInsider.com
www.streetinsider.com - July 24 at 7:23 PM
finance.yahoo.com logoEpizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
finance.yahoo.com - July 24 at 7:23 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Downgraded by BidaskClub
www.americanbankingnews.com - July 23 at 5:34 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 18 at 8:32 PM
finance.yahoo.com logoEpizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : July 18, 2017
finance.yahoo.com - July 18 at 7:54 PM
americanbankingnews.com logoZacks Investment Research Lowers Epizyme, Inc. (NASDAQ:EPZM) to Hold
www.americanbankingnews.com - July 17 at 3:26 PM
americanbankingnews.com logoEpizyme, Inc. (NASDAQ:EPZM) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 12 at 9:02 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) CFO Andrew E. Singer Sells 3,024 Shares
www.americanbankingnews.com - July 5 at 8:09 PM
americanbankingnews.com logoZacks: Analysts Expect Epizyme, Inc. (EPZM) to Post -$0.56 Earnings Per Share
www.americanbankingnews.com - July 4 at 2:20 PM
finance.yahoo.com logoEpizyme, Inc. – Value Analysis (NASDAQ:EPZM) : June 30, 2017
finance.yahoo.com - June 30 at 6:41 PM
finance.yahoo.com logoEpizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : June 29, 2017
finance.yahoo.com - June 29 at 7:50 PM
streetinsider.com logoEpizyme (EPZM) Expands Collaboration to Study Tazemetostat and TECENTRIQ Combination in NSCLC with Genentech - StreetInsider.com
www.streetinsider.com - June 26 at 6:00 PM
finance.yahoo.com logoEpizyme Expands Clinical Collaboration to Study Tazemetostat and TECENTRIQ® Combination in NSCLC
finance.yahoo.com - June 26 at 6:00 PM
finance.yahoo.com logoEpizyme Progressing Well on Two Lead Pipeline Candidates
finance.yahoo.com - June 26 at 6:00 PM
americanbankingnews.com logoCann Reiterates "Buy" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - June 25 at 7:26 PM
americanbankingnews.com logoEpizyme, Inc. (EPZM) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 24 at 10:22 PM
thestreet.com logoBiotech Movers: Sangamo, Epizyme, Revance - TheStreet.com
www.thestreet.com - June 21 at 6:32 PM
finance.yahoo.com logoBiotech Movers: Sangamo, Epizyme, Revance
finance.yahoo.com - June 21 at 6:32 PM
thestreet.com logoBiotech Movers: AveXis, Clovis, Epizyme - TheStreet.com
www.thestreet.com - June 20 at 10:46 PM
americanbankingnews.com logoFY2017 EPS Estimates for Epizyme, Inc. (EPZM) Lifted by Analyst
www.americanbankingnews.com - June 19 at 7:20 AM
finance.yahoo.com logoEpizyme (EPZM) Jumps: Stock Rises 17.4%
finance.yahoo.com - June 16 at 3:18 PM
americanbankingnews.com logoLeerink Swann Reiterates "Outperform" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - June 16 at 12:34 PM



Epizyme (EPZM) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff